


year in review

The Pharma & Biotech stock index grew by more than 32.5% in 2014, and the increasing number of public CROs saw their stock prices rise as well. In 2014, the clinical development industry saw an increased shift toward Risk-Based Monitoring methodologies and an increased reliance on eClinical technologies. For more information on these trends and ISR's CRO market size projections through 2018, visit www.ISRreports.com.


growth



eClinical


eClinical technology continued to play a growing role in clinical development in 2014. ISR's research found that "integration" is gaining the most importance among eClinical system users.

ISR's respondents said they integrate CTMS applications with:



going public

2014 saw even more CROs going public, a trend that PAREXEL's SVP and CFO, Ingo Bank, said he expects to continue in the coming years.



trends

Increasing use of multiple countries
Technology becoming increasingly critical

Growing use of RBM Expansion of preferred provider lists

China becoming more common for subject recruitment

More complex trials eClinical data integration on the rise



rbm

2014 saw an increase in the number of clinical trials using Risk-Based Monitoring. For details on the growth and implementation of RBM, see ISR's "The Evolution of Risk-Based Monitoring" infographic.

65%


65% of ISR respondents consider their volume of risk-based monitoring in Phase II/III studies to be increasing.

40%

ISR respondents report that 40% of their Phase II/III studies include risk-based monitoring.

IND applications

Number of Investigational New Drug applications, by quarter



m&a

Merger and Acquisition activity in the Pharmaceutical and Life Science Industry continued to grow in 2014. Total deal value (Q1-Q3):

